Ebola Virus May Linger in Body Longer Than Previously Known
The deadly Ebola virus disease (EVD), known for its high fatality rates, may persist in the human body for extended periods beyond clinical recovery, according to alarming new findings. A recent report published in the New England Journal of Medicine highlights that the virus could remain detectable in breast milk for several weeks even after patients have been declared virus-free through standard blood tests. This discovery raises significant concerns about potential post-illness transmission, particularly from mothers to infants during breastfeeding.
Understanding Ebola Virus Disease
Ebola virus disease is a severe, often fatal illness caused by viruses belonging to the Orthoebolavirus genus within the filoviridae family. The disease primarily affects humans and other primates, with an average fatality rate of approximately 50%, though historical outbreaks have seen mortality rates ranging from 25% to 90%. According to the World Health Organization (WHO), the initial transmission to humans typically occurs through contact with infected wild animals such as fruit bats, porcupines, and non-human primates. Subsequent human-to-human spread happens via direct contact with blood, secretions, organs, or other bodily fluids of infected individuals, as well as contaminated surfaces and materials like bedding and clothing.
Case Study Reveals Viral Persistence in Breast Milk
The new report details a concerning case involving a 23-year-old woman from the Democratic Republic of the Congo (DRC) who contracted EBOV during her pregnancy in 2019. After receiving standard monoclonal antibody therapy in Butembo, DRC, she was discharged following three consecutive negative reverse-transcriptase–polymerase-chain-reaction (RT-PCR) tests, confirming the virus was no longer detectable in her blood. She later delivered a healthy infant at 42 weeks gestation, with no evidence of EBOV infection in maternal blood, amniotic fluid, vaginal secretions, or the newborn.
Despite these negative results, doctors discovered viral RNA in both the placenta and breast milk. To mitigate the infant's risk of contracting the disease, healthcare providers advised the mother to cease breastfeeding and administered a prophylactic monoclonal antibody to the newborn. Follow-up tests showed no signs of infection in the infant, and the mother's blood tests remained negative. However, viral RNA was still detectable in her breast milk at 14 weeks after illness onset. Clinicians used the drug bromocriptine to suppress lactation as a protective measure for the newborn.
Implications for Public Health and Guidelines
These findings suggest the potential for transmission from mother to child during breastfeeding, even when standard viral load measures indicate clearance. The researchers emphasize that further studies, including viral culture tests, are necessary to better understand the actual infection risk posed by such viral persistence. Currently, WHO guidelines recommend that Ebola survivors avoid breastfeeding until viral clearance is confirmed, but this case indicates that confirmation may require more comprehensive testing beyond blood analysis.
The study underscores the need for heightened vigilance and possibly revised protocols for monitoring recovered Ebola patients, especially new mothers, to prevent unintended transmission. As global health authorities continue to combat Ebola outbreaks, understanding these lingering viral reservoirs becomes crucial for developing more effective post-recovery management strategies and protecting vulnerable populations, particularly infants.
